Nanobiotix S.A. (NBTX) Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Nanobiotix S.A. NASDAQ:NBTX Healthcare · Biotechnology
Mkt Cap $1.6B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ● Major
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
globenewswire.com • 8d ago Press Release
Voting Rights and Shares Capital of the Company
globenewswire.com • 12d ago Press Release
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
globenewswire.com • 1mo ago Press Release ● Major
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
globenewswire.com • 1mo ago Press Release
Voting Rights and Shares Capital of the Company
globenewswire.com • 1mo ago Press Release
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
globenewswire.com • 1mo ago Press Release
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com • 1mo ago Press Release
Voting Rights and Shares Capital of the Company
globenewswire.com • 2mo ago Press Release
Voting Rights and Shares Capital of the Company
globenewswire.com • 3mo ago Press Release
Voting Rights and Shares Capital of the Company
globenewswire.com • 4mo ago Press Release ● Major
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
globenewswire.com • 4mo ago Press Release
Nanobiotix Joins the Euronext Tech Leaders Index
globenewswire.com • 5mo ago Press Release ● Critical
NANOBIOTIX Announces Closing of Global Offering
globenewswire.com • 5mo ago Press Release ● Critical
NANOBIOTIX Announces Full Exercise of Underwriters' Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
globenewswire.com • 5mo ago Press Release ● Critical
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
globenewswire.com • 5mo ago Press Release
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
globenewswire.com • 5mo ago Press Release ● Critical
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
globenewswire.com • 5mo ago Press Release ● Critical
Nanobiotix Announces Launch of Global Follow-On Offering
globenewswire.com • 5mo ago Press Release ● Major
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
globenewswire.com • 5mo ago Press Release
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
globenewswire.com • 5mo ago Press Release
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
globenewswire.com • 6mo ago 
